Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.62 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.62 |
| ▸ | CIB1 | Q99828 | 4/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.55 |
| ▸ | CTSG | P08311 | 1/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.53 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.52 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 2/20 | 0.50 |
| ▸ | MC5R | P33032 | 2/20 | 0.50 |
| ▸ | MC3R | P41968 | 2/20 | 0.50 |
| ▸ | MC1R | Q01726 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23110257 | 0.95 | KLKB1 (0.61) | CD274PDCD1CIB1KLKB1KLK5 | |
| SCHEMBL23109953 | 0.94 | CD274 (0.54) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL23110202 | 0.94 | KLKB1 (0.64) | CD274PDCD1CIB1KLKB1PCSK9 | |
| SCHEMBL27332332 | 0.94 | KLKB1 (0.64) | CD274PDCD1CIB1KLKB1PCSK9 | |
| SCHEMBL23110146 | 0.92 | KLKB1 (0.65) | CD274PDCD1KLKB1PCSK9EPHA2 | |
| SCHEMBL23110262 | 0.92 | KLKB1 (0.63) | CD274PDCD1CIB1KLKB1PCSK9 | |
| SCHEMBL23110150 | 0.88 | PDCD1 (0.59) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL27332267 | 0.88 | PDCD1 (0.59) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL17810728 | 0.88 | CD274 (0.73) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL17810725 | 0.88 | CD274 (0.73) | CD274PDCD1CIB1KLKB1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018097-B2 | Non-chromatographic purification of macrocyclic peptides by a resin catch and release | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018097-B2 | Non-chromatographic purification of macrocyclic peptides by a resin catch and release | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-25 | — | — | US | disclosed |
| US-11479581-B2 | Non-chromatographic purification of macrocyclic peptides by a resin catch and release | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210079046-A1 | NON-CHROMATOGRAPHIC PURIFICATION OF MACROCYCLIC PEPTIDES BY A RESIN CATCH AND RELEASE | BRISTOL-MYERS SQUIBB COMPANY | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079046-A1 | NON-CHROMATOGRAPHIC PURIFICATION OF MACROCYCLIC PEPTIDES BY A RESIN CATCH AND RELEASE | ANPEP, DNPEP, NPR1 | CD274 2215/4885PDCD1 2789/4885CIB1 3289/4885 |
| US-11479581-B2 | Non-chromatographic purification of macrocyclic peptides by a resin catch and release | ANPEP, NPR1, DNPEP | CD274 2199/4885PDCD1 2810/4885CIB1 3148/4885 |
| US-12018097-B2 | Non-chromatographic purification of macrocyclic peptides by a resin catch and release | VIP, NPR1, NPPA | CD274 2624/4885PDCD1 3069/4885CIB1 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.